Details for Patent: 9,452,162

Which drugs does patent 9,452,162 protect, and when does it expire?

Patent 9,452,162 protects ONIVYDE and is included in one NDA.

This patent has forty-eight patent family members in twenty-one countries.

Summary for Patent: 9,452,162

Patent landscape, scope, and claims:

Title:	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Abstract:	Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
Inventor(s):	Bayever; Eliel (New York, NY), Dhindsa; Navreet (Boston, MA), Fitzgerald; Jonathan Basil (Cambridge, MA), Laivins; Peter (Rowayton, CT), Moyo; Victor (Concord, MA), Niyikiza; Clet (Gulph Mills, PA), Kim; Jaeyeon (Lexington, MA)
Assignee:	Merrimack Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	14/406,776
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 9,452,162

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ipsen	ONIVYDE	irinotecan hydrochloride	INJECTABLE, LIPOSOMAL;INTRAVENOUS	207793-001	Oct 22, 2015		RX	Yes	Yes						TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN

International Family Members for US Patent 9,452,162

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013202947
Australia	2013274287
Australia	2018201942
Brazil	112014031088
Canada	2875824